Randox Premieres an Online Interlaboratory Data Management Package at Medica
By Randox Laboratories Ltd. | 11.13.17
Solution is designed to help laboratories efficiently review QC data from all their lab instruments on one central platform.
Acusera 24.7 is designed to help laboratories efficiently review QC data from all their lab instruments on one central platform, thereby allowing quick and easy identification of QC failures and emerging trends. Unique access to peer group data updated instantly in real-time from our global network of laboratory participants will speed up troubleshooting and help pinpoint the root cause of any QC failures by easily identifying if an issue is isolated or widespread.
Randox is also showcasing other advancements in laboratory technology at the Medica, being held Nov. 13-16 in Düsseldorf, Germany. At its state-of-the-art interactive exhibition stand, Randox is hosting a series of demonstrations of its analyzers, including the Evidence Evolution and Rx modena, and a number of advances in laboratory medicine, involving increasing the test menu available to clinicians and improving the connectivity of laboratories across the world to improve overall quality.
“Through our advancements in laboratory innovation, we’re driving an industry-wide evolution” said Randox CEO Dr. Peter FitzGerald. “Our products are leading the way in innovation and enabling laboratories to transform the way they operate. We will be hosting demonstrations of a wide range of our fully-automated analyzers, which are packed with cutting-edge technology and intuitive software. The goal is to provide future-proof diagnostic technology that will create the most efficient and effective laboratories.”
Paving the way is Randox’s patented Biochip Array Technology (BAT). This multi-analyte testing platform is the product of a £250 million research and development project. The ceramic tile measuring 9×9 mm can currently run up to 49 assays simultaneously,100 assays in the near future. This innovation allows the simultaneous quantitative or qualitative detection from a wide range of analytes from a single sample. It is suitable for use in a wide range of laboratories including clinical, research, hospital, veterinary and forensic and clinical toxicology.
To enhance the benefits of BAT, Randox introduced the Evidence Evolution to its stable of immunoassay analyser platforms. The Evidence Evolution is the world’s first fully automated random-access biochip testing platform, capable of delivering 2640 results in one hour, with the first delivered in just 37 minutes.
Joining the evolution in Hall 3 stand A08 is the RX modena. This highly reliable, precise, fully automated clinical chemistry analyser can run 1,200 tests per hour including ISE. When combined with its RX series test menu, it offers a winning combination for all large, multi-disciplinary laboratories.
“We develop more new tests than any other diagnostics manufacturer, and one of the products that we’re showcasing at this year’s Medica is Adiponectin,” added Susan Hammond, global sales manager at Randox. “This novel biomarker is a powerful new weapon in the fight against some of the biggest health issues faced throughout the world including diabetes, cancers and cardiovascular disease. As it’s World Diabetes Day on Tuesday 14th November, it’s a great opportunity to draw attention to this array which labs can run as part of their routine testing panel.”
Randox is a global developer and provider of healthcare diagnostics solutions. With more than 1,400 employees of 44 nationalities, including 300 research scientists and engineers, the company has offices and distribution in over 145 countries. There are four key manufacturing and research and development sites, located in County Antrim, Northern Ireland; Dungloe, County Donegal, Ireland; Bangalore, India; and in the Greater Washington D.C., area.